默沙东公司宣布,其根据《处方药使用者付费法案》提交的申请,已获得美国食品药品监督管理局确认的目标行动日期——2026年4月28日。这一关键时间节点标志着监管机构完成审评的最终期限,对公司核心管线的商业化进程具有重要指示意义。
默沙东公司宣布,其根据《处方药使用者付费法案》提交的申请,已获得美国食品药品监督管理局确认的目标行动日期——2026年4月28日。这一关键时间节点标志着监管机构完成审评的最终期限,对公司核心管线的商业化进程具有重要指示意义。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.